Following a resubmission:
pregabalin (Lyrica) is accepted for restricted use within NHS Scotland for the treatment of peripheral neuropathic pain in adults.
The clinical evidence of efficacy in patients with peripheral neuropathic pain who are refractory to treatment was based on open-label, uncontrolled, non-randomised studies, with small patient numbers and different methodologies.
Pregabalin is restricted to use in patients who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments for peripheral neuropathic pain. Treatment should be stopped if the patient has not shown sufficient benefit within 8 weeks of reaching the maximally tolerated therapeutic dose.
Download detailed advice95KB (PDF)
Medicine details
- Medicine name:
- pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg and 300mg capsules (Lyrica®)
- SMC ID:
- 157/05
- Indication:
Peripheral neuropathic pain in adults.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 11 May 2009